Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million, targeting UTI treatments with FDA-approved Pivya and developmental MEC.

• Pivya is an FDA-approved treatment for uncomplicated UTIs in the US market.
• MEC is a developmental product targeting complicated UTIs in the US market.
• The acquisition payment of $12 million is staggered over time based on milestones achieved.